Illumina Debt/Equity
What is the Debt/Equity of Illumina?
The Debt/Equity of Illumina, Inc. is 0.42
What is the definition of Debt/Equity?
Debt to equity ratio is a financial ratio indicating the relative proportion of shareholders’ equity and debt used to finance a company’s assets.
lfy (last fiscal year)
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Debt/Equity of companies in the Miscellaneous sector on LSE compared to Illumina
What does Illumina do?
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has collaboration agreements with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer; LetsGetChecked to track COVID-19 variants in California; and Merck & Co., Inc. to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency. The company was incorporated in 1998 and is headquartered in San Diego, California.
Companies with debt/equity similar to Illumina
- Sandu Pharmaceuticals has Debt/Equity of 0.42
- Kader has Debt/Equity of 0.42
- Canaan has Debt/Equity of 0.42
- Xinyi Glass has Debt/Equity of 0.42
- Lundin Ab Spon Adr Each has Debt/Equity of 0.42
- Wereldhave Belgium has Debt/Equity of 0.42
- Illumina has Debt/Equity of 0.42
- New Solar has Debt/Equity of 0.42
- Castle Minerals has Debt/Equity of 0.42
- Biglari has Debt/Equity of 0.42
- ImExHS has Debt/Equity of 0.42
- Genesys International has Debt/Equity of 0.42
- Konami has Debt/Equity of 0.42